Table 5.
Disease stage | Cerliponase alfa | |||||
---|---|---|---|---|---|---|
Mean value | Standard error | Median value | Minimum value | Maximum value | Difference between EQ-5D-5L and mapped EQ-5D-3L utility values | |
6 | 0.985 | 0.015 | 1.000 | 0.879 | 1.000 | 0.005 |
5 | 0.762 | 0.011 | 0.747 | 0.747 | 0.836 | 0.088 |
4 | 0.629 | 0.019 | 0.636 | 0.541 | 0.710 | 0.116 |
3 | 0.464 | 0.036 | 0.510 | 0.325 | 0.555 | 0.038 |
2 | 0.424 | 0.056 | 0.468 | 0.101 | 0.555 | 0.050 |
1 | 0.218 | 0.078 | 0.267 | − 0.166 | 0.531 | 0.120 |
0 | − 0.163 | 0.033 | − 0.159 | − 0.352 | − 0.071 | 0.292 |
0 + VL | − 0.198 | 0.060 | − 0.147 | − 0.594 | − 0.071 | 0.317 |
0 + VL + PC | − 0.211 | 0.058 | − 0.154 | − 0.594 | − 0.095 | 0.315 |
Disease progression increases with decreasing disease stage. Utility values are given on a scale where 1 is equivalent to perfect health, and 0 equivalent to death. Summary values were produced from the returned EQ-5D-5L questionnaires and results were mapped to equivalent EQ-5D-3L utility values using the Van Hout algorithm [23]. UK value set
PC, palliative care; VL, vision loss